MK-677 (Ibutamoren) + AOD-9604 Stack: Complete Protocol for Women

What MK-677 and AOD-9604 Actually Do Inside a Woman's Body

MK-677 and AOD-9604 work through different mechanisms, and understanding that difference matters before you decide to combine them. MK-677 acts as a ghrelin receptor agonist, stimulating the pituitary to pulse more growth hormone and driving a sustained rise in IGF-1. AOD-9604 mimics only the lipolytic C-terminal region (amino acids 176 to 191) of hGH, without activating the IGF-1 pathway.

How MK-677 Works

Ibutamoren is not a peptide in the injectable sense. It is an oral small molecule that binds the ghrelin receptor (GHSR-1a). A phase II trial published in the Journal of Clinical Endocrinology and Metabolism found that MK-677 increased 24-hour mean GH concentration by approximately 97% and IGF-1 by 52% in older adults after two months at 25 mg/day. That trial enrolled both sexes, but subgroup data by sex were not published in a form allowing direct comparison of effect size in women.

Women already show higher GH pulse amplitude than men at reproductive age, driven partly by estrogen. After menopause, GH pulsatility drops sharply. Whether MK-677 restores a physiologically appropriate pattern in a postmenopausal woman or creates supraphysiologic IGF-1 spikes is unknown; no RCT has examined this in women specifically.

How AOD-9604 Works

AOD-9604 was originally developed by Monash University as an anti-obesity drug. A 12-week RCT in obese adults found that 250 mcg/day subcutaneously produced statistically significant fat loss versus placebo without raising IGF-1, fasting glucose, or insulin. The trial enrolled men and women, but sex-stratified results were not published. AOD-9604 subsequently failed to gain FDA approval for obesity because the phase III program did not meet primary endpoints, and the FDA's clinical review documents the compound as having no approved indication.

Why the Combination Is Theoretically Appealing

Stacking them is meant to give you GH axis stimulation from MK-677 alongside targeted fat mobilization from AOD-9604, while keeping IGF-1 lower than you would get from exogenous hGH alone. The logic holds mechanistically. No study has tested this combination in humans, male or female. This gap matters, and you should weigh it honestly before starting a protocol.

Sex-Specific Physiology: Why Women Are Not Small Men Here

Women's GH axis behaves differently from men's across every life stage. Estrogen amplifies GH pulsatility and upregulates GH receptor sensitivity in the liver, driving higher IGF-1 production per unit of GH secreted. This means a woman taking MK-677 at the same dose as a man may produce a proportionally larger IGF-1 response. No pharmacokinetic study has formally quantified this difference for ibutamoren.

Reproductive Years (Ages 18-40)

During the reproductive years, GH pulsatility peaks in the luteal phase and is blunted in the follicular phase. GH also stimulates insulin-like effects in follicular cells, which has direct implications for women with PCOS.

Women with PCOS already carry elevated IGF-1 relative to BMI-matched controls, documented in a study in Fertility and Sterility. Layering MK-677 onto an already upregulated IGF-1 system may worsen hyperinsulinemia and androgenic signaling. If you have PCOS, this stack warrants specific caution and requires glucose monitoring before and during use.

Perimenopause (Typically Ages 45-55)

Estrogen fluctuation in perimenopause makes GH pulsatility erratic. Some practitioners report that women in perimenopause notice more pronounced water retention and joint discomfort with MK-677 than younger women, likely because fluctuating estrogen changes fluid regulation. Hard comparative data do not yet exist.

Postmenopause

After menopause, GH secretion declines by roughly 14% per decade, according to data reviewed in a 2019 paper in the journal Menopause. The theoretical case for GH axis support is arguably strongest here. Yet the long-term IGF-1 elevation that MK-677 produces is also the life stage where IGF-1's relationship with breast cancer risk becomes a more immediate clinical question, discussed below.

Evidence Review: What the Trials Actually Show

Most of the evidence for each compound individually comes from small trials, mostly in men, and from animal studies. No peer-reviewed human study has examined the MK-677 plus AOD-9604 combination.

MK-677 Human Evidence

The best-powered human trial of MK-677, the MK-677 in elderly adults study by Nass et al. Published in Annals of Internal Medicine, followed 65 men and women aged 60 to 81 for two years. MK-677 at 25 mg/day increased IGF-1 to young-adult levels, increased lean mass by approximately 1.1 kg versus placebo, and did not improve functional strength or bone density over placebo. Adverse events included a higher rate of congestive heart failure-related serious adverse events (9 versus 3 in placebo), increased fasting glucose, and insulin resistance. Sex-stratified safety data were not reported in the primary publication.

A smaller four-week crossover study at 10 and 25 mg showed dose-dependent IGF-1 rises and increased appetite, the latter likely driven by ghrelin receptor agonism. For women actively trying to reduce caloric intake, stimulated appetite is a real practical problem.

AOD-9604 Human Evidence

The most cited human data come from the Monash University-sponsored phase II dose-ranging trial showing that 250 mcg/day produced greater fat loss than placebo over 12 weeks. A phase IIb trial failed to replicate these results robustly enough for regulatory approval. AOD-9604 is registered as GRAS (Generally Recognized as Safe) for food use in the United States as a food additive at specific concentrations, but this designation does not constitute approval for medicinal use.

Animal Evidence for the Stack Concept

Animal studies of AOD-9604 in obese rodent models show consistent reduction in visceral fat without IGF-1 elevation, as reviewed in Heffernan et al.. Animal studies of GH secretagogues show sex-dimorphic effects on body composition, with females generally showing smaller lean mass gains and more pronounced fat mobilization responses than males. This is consistent with estrogen's known role in directing GH action toward fat mobilization over muscle anabolism.

Dosing Protocol: What Practitioners Report for Women

Because no RCT defines optimal dosing in women, the following reflects practitioner-reported protocols and is not a clinical recommendation from WomanRx. Doses cited here are lower than those commonly reported for male users, reflecting the sex-specific physiology above.

MK-677 Dosing in Women

Most women's-health practitioners familiar with peptide prescribing start women at 10 mg orally at night, taken with a small amount of food to blunt the appetite stimulation that peaks in the first hour post-dose. Some titrate to 15 mg after four to six weeks if IGF-1 response is subtherapeutic and glucose remains stable.

The 25 mg dose used in the Nass et al. Trial is generally considered too high for most women to start, given the greater relative IGF-1 response expected from estrogen-driven receptor sensitivity.

Timing matters. Taking MK-677 at night aligns its GH pulse stimulation with the physiologic nocturnal GH surge, which research in the Journal of Clinical Endocrinology and Metabolism shows is not abolished by the drug but is augmented. Nighttime dosing also helps some women sleep through the initial hunger spike.

AOD-9604 Dosing in Women

Practitioners report subcutaneous injection of 250 mcg once daily, administered in the morning in a fasted state, at least 30 minutes before eating. Some protocols specify alternating injection sites (abdomen, lateral thigh) to reduce localized tissue irritation.

A 300 mcg dose has been used but does not appear to produce meaningfully better fat loss outcomes based on the dose-ranging data from the original phase II trial.

Cycle Length and Rest Periods

Practitioners typically run this stack for 8 to 12 weeks, followed by a 4-week break for MK-677 and either continued daily AOD-9604 or a similar break, depending on IGF-1 levels. There is no clinical trial data defining optimal cycle length in women. IGF-1 should be checked at week 8 at minimum.

| Compound | Typical Women's Starting Dose | Timing | Route | |---|---|---|---| | MK-677 | 10 mg | Nightly with food | Oral | | AOD-9604 | 250 mcg | Morning, fasted | Subcutaneous injection |

Who This Stack May Suit (And Who Should Avoid It)

Candidacy for this stack depends heavily on your current life stage, metabolic health, and goals.

Women This Stack May Be Appropriate For

Women who are not pregnant, not trying to conceive, and not breastfeeding, who have a BMI over 27 with documented difficulty losing visceral fat despite optimized diet and exercise, and who do not have a personal or family history of hormone-sensitive cancers may find a time-limited trial worth discussing with a knowledgeable clinician. Women in perimenopause or postmenopause experiencing declining lean mass alongside fat redistribution toward the abdomen are the population most frequently mentioned in practitioner literature.

Women with hypothyroidism who are on stable thyroid hormone replacement should know that MK-677 has been reported to reduce T4 to T3 conversion in some individuals, based on the same Nass et al. Data. TSH and free T3 monitoring is warranted if you take levothyroxine.

Women Who Should Not Use This Stack

Avoid this stack if you:

• Are pregnant, trying to conceive, or breastfeeding (see mandatory section below)
• Have active or prior hormone-sensitive malignancy, including ER-positive breast cancer
• Have uncontrolled type 2 diabetes or prediabetes with fasting glucose above 100 mg/dL, given MK-677's documented insulin resistance effect
• Have a history of carpal tunnel syndrome (fluid retention from GH axis stimulation often worsens it)
• Take insulin or sulfonylureas (hypoglycemic risk from pharmacodynamic interaction)
• Have active acromegaly or pituitary pathology

Women with PCOS warrant an individual risk-benefit discussion, as above, and should not start without baseline fasting insulin and glucose.

Pregnancy, Lactation, and Contraception

Both MK-677 and AOD-9604 are contraindicated in pregnancy and breastfeeding. This is not a precautionary hedge. It is a hard stop.

Pregnancy

Neither compound has been assigned a formal FDA pregnancy category under the old lettering system because neither is approved for clinical use. Human reproductive safety data do not exist. Animal studies of GH secretagogues show dose-dependent fetal anomalies at supraphysiologic exposures in rodent models.

Elevated IGF-1 during organogenesis is biologically plausible as a teratogen, given IGF-1's role in fetal cell proliferation and differentiation. The ACOG position on unapproved compounds in pregnancy is unambiguous: compounds without adequate human safety data should not be used.

If you are trying to conceive, stop both compounds at least one full menstrual cycle before attempting pregnancy. MK-677's half-life is approximately 6 hours, so it clears quickly, but IGF-1 takes longer to normalize. AOD-9604's half-life is not well-characterized in women.

Lactation

No lactation transfer data exist for either compound. GH peptides and small-molecule GH secretagogues are present in human milk in animal models in some analogous compound classes. Given the theoretical risk to a nursing infant from altered GH signaling, use during breastfeeding is not appropriate.

Contraception Requirements

If you are of reproductive age and sexually active, use reliable contraception throughout any peptide protocol. Standard hormonal contraception (combined oral contraceptives, progestin-only pills, IUDs, implants) is appropriate. Note that combined oral contraceptives raise endogenous GH secretion through estrogen action, which means your IGF-1 response to MK-677 may be higher on OCP than off. Monitor IGF-1 accordingly.

Side Effects: What Women Report

The side effect profile of this stack in women overlaps with but differs from the male-reported profile.

MK-677 Side Effects in Women

• Water retention and puffiness, especially facial and periorbital, is the most frequently reported complaint. It tends to peak in the first two to four weeks and often improves after dose reduction.
• Increased appetite affects some women meaningfully. The ghrelin receptor agonism that drives GH pulses also stimulates hunger. Women starting a caloric deficit may find this counterproductive.
• Fasting glucose elevation was documented in the Nass et al. Trial and is a real metabolic risk.
• Fatigue and vivid dreams in the first few weeks, related to sleep-stage changes from altered GH pulsatility.
• Worsening of hormonal acne is occasionally reported by women in reproductive years, possibly driven by IGF-1-mediated sebaceous gland activity.

AOD-9604 Side Effects in Women

AOD-9604 has a notably cleaner side effect profile in the clinical trial data. The phase II trial found no significant difference from placebo in glucose, insulin, or IGF-1 levels. Injection site reactions (redness, mild bruising) are the most common complaint.

Monitoring Protocol

Women using this stack off-label need structured monitoring. A reasonable minimum schedule:

Baseline (before starting):

• Fasting glucose and insulin (calculate HOMA-IR)
• IGF-1
• Complete metabolic panel
• Fasting lipid panel
• TSH and free T3 (especially if on levothyroxine)
• For perimenopausal/postmenopausal women: consider DEXA scan for body composition baseline

Week 8:

• Fasting glucose and insulin
• IGF-1 (target the upper third of age-matched reference range, not supraphysiologic)
• TSH and free T3 if thyroid symptoms emerge

After each 12-week cycle:

• Full panel repeat before deciding to continue

If IGF-1 exceeds the upper limit of normal for your age, reduce MK-677 dose or discontinue. Sustained supraphysiologic IGF-1 is associated with increased breast cancer risk in observational data, with a meta-analysis in The Lancet reporting an odds ratio of approximately 1.49 for breast cancer per standard deviation increase in IGF-1 among premenopausal women.

The Evidence Gap: What We Don't Know

Women have been consistently underrepresented in peptide and GH secretagogue trials. The honest summary is:

• No RCT exists for this specific combination in any population.
• No pharmacokinetic study exists for MK-677 in women across menstrual cycle phases or hormonal status.
• No safety data exist for AOD-9604 in pregnancy or lactation.
• Long-term IGF-1 elevation from MK-677 in women has not been studied beyond two years.
• The effect of estrogen status (natural cycle, OCP, HRT, menopause) on MK-677's IGF-1 response is uncharacterized.

Practitioners and patients working with this stack are, in effect, generating the evidence. That is a real risk. Structuring your use with the monitoring protocol above at minimum gives you the ability to detect problems early.

Frequently Asked Questions